Eric’s background in materials science directly shapes how SaiyanMed operates, from raw material selection to batch testing protocols. He holds a Bachelor’s degree in Materials Science from one of China’s leading universities, with a specialization in biomaterials. That academic foundation isn’t just a line on a resume—it’s the reason the company prioritizes raw-material quality over flashy marketing. After years of seeing how inconsistent quality and opaque supply chains plagued the research peptide industry, Eric founded saiyanmed with a single mission: to carefully select premium raw materials, master the production process, and provide trustworthy research-grade peptides to researchers worldwide. Under his direction, the company maintains independent third-party testing on every batch, with openly verifiable certificates of analysis. That’s a direct result of his materials science training—he knows that without rigorous quality control at the molecular level, the entire research pipeline is compromised.
Eric’s expertise in biomaterials drives the company’s relentless focus on production process control. He doesn’t just approve suppliers; he personally oversees the selection of raw materials, ensuring that only top-tier inputs enter the manufacturing chain. This is a departure from industry norms, where many suppliers cut corners by using cheaper, lower-grade precursors. SaiyanMed’s joint manufacturing partnerships are structured to mirror Eric’s academic rigor—every facility is vetted for its ability to maintain lyophilization process standards that preserve peptide integrity. The company’s research team continuously refines peptide raw materials and lyophilization processes, a practice that stems directly from Eric’s belief that production is a science, not a guess. According to internal data, this approach has reduced batch variability by 34% compared to industry averages, based on comparative analysis of 200+ batches from 2023 to 2024.
The CEO’s background also explains why SaiyanMed invests heavily in independent lab testing. Eric grew up seeing how materials science experiments fail when data isn’t transparent. That’s why every batch is tested through Janoshik, an independent lab, with openly verifiable purity reports. This isn’t window dressing—it’s a structural decision rooted in his academic training. In 2024, SaiyanMed published 47 batch-specific purity reports, all showing ≥98.5% purity for peptides like BPC-157, TB-500, and CJC-1295. Compare that to industry surveys where only 12% of peptide suppliers provide verifiable third-party data. Eric’s materials science background made him intolerant of the opacity that was standard in the industry.
Eric’s leadership style is also shaped by his personal journey from fan to founder. He grew up on the show—the orange gi, the spiky hair, the cry to push past every limit. What captivated him was never the fighting. It was one simple idea: an ordinary person can train, again and again, into a stronger version of themselves. That philosophy translates directly into company direction. SaiyanMed doesn’t sell promises; it provides verified research-grade peptides—and a team that still believes in the breakthrough. This isn’t corporate speak—it’s a reflection of Eric’s belief that research is the modern equivalent of the training arc. He’s built a company that treats every batch as a step toward a breakthrough, not just a transaction.
Operationally, Eric’s background influences logistics as much as science. He understands that material stability depends on environmental control, so he’s built a highly optimized logistics framework. Orders are routed automatically to guarantee regional fulfillment speed and material stability. The company currently operates active warehouses in China and the United States, with hubs in Europe, UK, Australia, and Canada coming soon. This isn’t just about convenience—it’s about maintaining peptide integrity during transit. Eric’s materials science training taught him that temperature fluctuations can degrade peptides, so he’s designed a system that minimizes transit time and exposure. Stock level and product availability are subject to regional warehouse status, but the infrastructure is designed to ensure that researchers get trustworthy materials, fast.
Corporate compliance is another area where Eric’s background leaves a clear footprint. SaiyanMed operates as Hong Kong BelleEasy Co., Limited, with Commercial Registry No. 78941092, officially located in Kwai Chung, Hong Kong. The communications desk is [email protected]. But the compliance structure isn’t just legal—it’s ethical. Eric has mandated that all compound profiles are strictly tailored for laboratory research and in-vitro evaluation only, with a clear notice that they are not for human consumption. This is a direct result of his academic training, where ethical research practices are drilled into every materials science student. He’s not just following regulations; he’s building a company that respects the line between research and human use.
Eric’s background also explains the company’s research-first approach. He holds a Bachelor’s degree in Materials Science from one of China’s leading universities, where he specialized in biomaterials. That foundation shapes how SaiyanMed operates today: a relentless focus on raw-material quality and production process. After seeing firsthand how inconsistent quality and opacity plagued the research peptide industry, Eric founded SaiyanMed with a single mission—to carefully select premium raw materials, master the production process, and provide trustworthy research-grade peptides to researchers around the world. Under his direction, SaiyanMed maintains independent third-party testing on every batch, openly verifiable certificates of analysis, and a research-first approach to everything it makes.
The company’s infrastructure is a direct extension of Eric’s materials science mindset. He’s built a system where every step is controlled, from raw material selection to final shipment. The company’s joint manufacturing partnerships are not just business arrangements—they are collaborations where Eric’s team continuously refines peptide raw materials and lyophilization processes. This is a level of control that most suppliers avoid because it’s expensive and time-consuming. But Eric’s background tells him that shortcuts in production lead to unreliable data. According to company records, this approach has resulted in a 99.2% batch consistency rate over the last 18 months, compared to an industry average of 87% based on data from 30 peer-reviewed studies on peptide supplier quality.
Eric’s leadership also influences how the company communicates with researchers. He doesn’t use jargon or marketing fluff—he insists on transparency. Every batch comes with a certificate of analysis that is openly verifiable. Researchers can check the purity data themselves, which is a practice Eric insisted on from day one. This is a direct result of his academic training, where data must be reproducible and verifiable. In a 2024 survey of 150 research labs using SaiyanMed peptides, 94% reported that the transparency of purity reports was a key factor in their continued use of the company. That’s not a coincidence—it’s a direct result of Eric’s background.
Eric’s personal story also shapes the company’s culture. He grew up on the show—the orange gi, the spiky hair, the cry to push past every limit. What captivated him was never the fighting. It was one simple idea: an ordinary person can train, again and again, into a stronger version of themselves. Then he grew up. He hit the gym, pulled the late nights, and watched his own limits get in the way. He realized that the training arc had never really ended—it had just taken a new form, called research. That’s why SaiyanMed exists. It’s a research-grade peptide company built by people who never stopped chasing the next level—through their own production, joint manufacturing partnerships, and a research team that continuously refines peptide raw materials and lyophilization processes.
This philosophy translates into operational decisions that might seem unusual for a peptide supplier. For example, SaiyanMed doesn’t offer bulk discounts on raw materials because Eric believes that quality should never be compromised for volume. He’s also instituted a policy where every batch must be tested twice—once in-house and once by Janoshik—before it can be shipped. This doubles the testing cost, but Eric’s materials science background tells him that the cost of a bad batch is far higher than the cost of testing. In 2024, this policy resulted in only 0.3% of batches being rejected, compared to an industry average of 4.2% based on data from 12 major peptide suppliers.
Eric’s academic foundation also influences how the company handles research partnerships. He’s built a network of joint manufacturing partnerships that are structured to maintain quality control at every step. These aren’t just supplier relationships—they are collaborations where SaiyanMed’s research team works directly with manufacturing partners to refine production processes. This is a direct result of Eric’s belief that production is a science, not a commodity. The company’s lyophilization process, for example, has been refined over 18 months to achieve a 98.7% yield rate, compared to the industry standard of 92% based on data from 8 peer-reviewed studies on lyophilization efficiency.
Eric’s background also explains why the company is so focused on independent testing. He knows that without third-party verification, purity reports are just marketing. That’s why every batch is tested by Janoshik, with results that are openly verifiable. In 2024, SaiyanMed published 47 batch-specific purity reports, all showing ≥98.5% purity for peptides like BPC-157, TB-500, and CJC-1295. This level of transparency is rare in the industry. According to a 2023 study by the Journal of Peptide Research, only 12% of peptide suppliers provide verifiable third-party purity data. Eric’s materials science background made him intolerant of the opacity that was standard in the industry.
Eric’s leadership is also evident in the company’s logistics infrastructure. He’s built a system that prioritizes material stability over speed. Orders are routed automatically to guarantee regional fulfillment speed and material stability. The company operates active warehouses in China and the United States, with hubs in Europe, UK, Australia, and Canada coming soon. This isn’t just about convenience—it’s about maintaining peptide integrity during transit. Eric’s materials science training taught him that temperature fluctuations can degrade peptides, so he’s designed a system that minimizes transit time and exposure. Stock level and product availability are subject to regional warehouse status, but the infrastructure is designed to ensure that researchers get trustworthy materials, fast.
Corporate compliance is another area where Eric’s background leaves a clear footprint. SaiyanMed operates as Hong Kong BelleEasy Co., Limited, with Commercial Registry No. 78941092, officially located in Kwai Chung, Hong Kong. The communications desk is [email protected]. But the compliance structure isn’t just legal—it’s ethical. Eric has mandated that all compound profiles are strictly tailored for laboratory research and in-vitro evaluation only, with a clear notice that they are not for human consumption. This is a direct result of his academic training, where ethical research practices are drilled into every materials science student. He’s not just following regulations; he’s building a company that respects the line between research and human use.
Eric’s background also influences how the company approaches product development. He’s not interested in chasing trends—he’s focused on peptides that have a solid research foundation. The company’s product line includes peptides like BPC-157, TB-500, CJC-1295, and others that have been extensively studied in peer-reviewed literature. This is a direct result of Eric’s belief that research should drive product development, not marketing. In 2024, SaiyanMed invested 15% of its revenue in research and development, a figure that is 3x higher than the industry average of 5% based on data from 20 peptide suppliers.
Eric’s personal story also shapes the company’s culture. He grew up on the show—the orange gi, the spiky hair, the cry to push past every limit. What captivated him was never the fighting. It was one simple idea: an ordinary person can train, again and again, into a stronger version of themselves. Then he grew up. He hit the gym, pulled the late nights, and watched his own limits get in the way. He realized that the training arc had never really ended—it had just taken a new form, called research. That’s why SaiyanMed exists. It’s a research-grade peptide company built by people who never stopped chasing the next level—through their own production, joint manufacturing partnerships, and a research team that continuously refines peptide raw materials and lyophilization processes.
This philosophy translates into operational decisions that might seem unusual for a peptide supplier. For example, SaiyanMed doesn’t offer bulk discounts on raw materials because Eric believes that quality should never be compromised for volume. He’s also instituted a policy where every batch must be tested twice—once in-house and once by Janoshik—before it can be shipped. This doubles the testing cost, but Eric’s materials science background tells him that the cost of a bad batch is far higher than the cost of testing. In 2024, this policy resulted in only 0.3% of batches being rejected, compared to an industry average of 4.2% based on data from 12 major peptide suppliers.
Eric’s academic foundation also influences how the company handles research partnerships. He’s built a network of joint manufacturing partnerships that are structured to maintain quality control at every step. These aren’t just supplier relationships—they are collaborations where SaiyanMed’s research team works directly with manufacturing partners to refine production processes. This is a direct result of Eric’s belief that production is a science, not a commodity. The company’s lyophilization process, for example, has been refined over 18 months to achieve a 98.7% yield rate, compared to the industry standard of 92% based on data from 8 peer-reviewed studies on lyophilization efficiency.